Cetera Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Cetera Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-746	Closed	-$19.1K	–	1854
2023 Q3	$19.1K	Hold	746	–	–	﹤0.01%	1683
2023 Q2	$12.9K	Hold	746	–	–	﹤0.01%	1643
2023 Q1	$9.06K	Hold	746	–	–	﹤0.01%	1638
2022 Q4	$26.6K	Hold	746	–	–	﹤0.01%	1568
2022 Q3	$25K	Hold	746	–	–	﹤0.01%	1245
2022 Q2	$27K	Hold	746	–	–	﹤0.01%	1337
2022 Q1	$114K	Buy	+746	New	+$153K	﹤0.01%	1350

Other funds holding PRAX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Cetera Advisors's PRAX Position: Q4 2023 in Review

Cetera Advisors sold out of Praxis Precision Medicines (PRAX) in Q4 2023, closing a stake of 746 shares — an estimated $19.1K sold.

Cetera Advisors first reported a position in PRAX in Q1 2022 and held it in 7 quarters. The position peaked at $114K in Q1 2022. 60 funds tracked by Wall St. Rank hold PRAX as of Q4 2023.

Cetera Advisors reported no remaining Praxis Precision Medicines position as of Q4 2023 after selling out during the quarter.
Cetera Advisors sold 746 Praxis Precision Medicines shares in Q4 2023, an estimated $19.1K.
Cetera Advisors first reported a position in Praxis Precision Medicines in Q1 2022 and held it in 7 quarters.
Cetera Advisors's Praxis Precision Medicines position peaked at $114K in Q1 2022.
60 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2023.

Based on Cetera Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.